A clinical trial from India raises the possibility of huge cost savings by using ultralow immunotherapy doses in the treatment of head and neck cancer.
Medscape Medical News
Ultralow Dose of Nivolumab Offers Huge Cost Savings
A clinical trial from India raises the possibility of huge cost savings by using ultralow immunotherapy doses in the treatment of head and neck cancer.
Medscape Medical News
